Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-28T14:31:14.528Z Has data issue: false hasContentIssue false

Therapeutic options in panic disorder

Published online by Cambridge University Press:  16 April 2020

HGM Westenberg*
Affiliation:
Department of Biological Psychiatry, Academic Hospital Utrecht, PO Box 85500, Utrecht, NL-3508, The Netherlands
Get access

Extract

The principal management strategy for patients with panic attacks and agoraphobia has traditionally been behavioural therapy, but the delineation of panic disorder as a distinct diagnostic entity has stimulated psychopharmacological research on this psychiatric condition. As a result, the treatment of panic disorder has diversified. Effective pharmacological treatment of this disorder began with the antidepressant imipramine, but today a wide variety of efficacious agents are available for treating the symptoms of panic disorder. The four primary classes of agents for panic disorder are the tricyclic antidepressants (TCAs), the serotonin reuptake inhibitors (SSRIs), the monoamine oxidase inhibitors (MAOIs) and the high-potency benzodiazepines (BZs). Effective non-pharmacological treatments are primarily behavioural, although cognitive approaches have also been shown to be successful.

Type
Research Article
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bakish, DThe use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia. J Clin Psychopharmacol 1994; 14: 74-5CrossRefGoogle ScholarPubMed
Black, BUhde, TWTancer, MEFluoxetine for the treatment of social phobia J Clin Psychopharmacol 1992; 12: 293-5CrossRefGoogle ScholarPubMed
den Boer, JAWestenberg, HGMKamerbeek, WDVerhoeven, WMKahn, RSEffect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine Int Clin Psychopharmacol 1987; 2: 21-32CrossRefGoogle ScholarPubMed
den Boer, JAWestenberg, HGMEffect of serotonin and noradrena-line uptake inhibitors in panic disorders; a double-blind comparative study with fluvoxamine and maprotiline Int Clin Psychopharmacol 1988; 3: 59-74CrossRefGoogle Scholar
den Boer, JAWestenberg, HGMSerotonin function in panic disorder, a double-blind placebo-controlled study with fluvoxamine and ritanserin Psychopharmacol 1990; 102: 85-94CrossRefGoogle ScholarPubMed
Elkin, IShea, MTWatkins, JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program; General Effectiveness of Treatments Arch Gen Psychiatry 1989; 46: 971-82CrossRefGoogle ScholarPubMed
Evans, LKenardy, JSchneider, PHoey, HEffect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks Acta Psychiatr Scand 1986; 73: 49-53CrossRefGoogle ScholarPubMed
Gorman, JWolkow, RSertraline as a treatment for panic disorder Neuropsychopharmacol 1994; 10: 197SGoogle Scholar
Hoehn Saric, RMcLeod, DRHipsley, AEffect of fluvoxamine on panic disorder J Clin Psychopharmacol 1993; 5: 321-6Google Scholar
Lecrubier, The Panic Disorder GroupA double-blind placebo controlled study of paroxetine and clomipramine in the treatment of panic disorder. AEP, Copenhagen 18–22 Sept 1994Google Scholar
Liebowitz, MRHeimberg, RG.Treatment of social phobia. In: Heimberg, RGLiebowitz, MRHope, GSchneier, FSocial phobia: diagnosis, assessment and treatment. New York: Guilford Press, 1995 in pressGoogle Scholar
Woods, SBlack, DBrown, SAsnis, GPotkin, SHameedi, FFluvoxamine in the treatment of panic disorder in out-patients: a double-blind, placebo-controlled study Neuropsychopharmacol 1994; 10: 103SGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.